Arnuity® Ellipta® Drug Use Investigation

GlaxoSmithKline (GSK)

Status: Completed

Conditions: Asthma

Treatments: Drug: Arnuity Ellipta

Study type: Observational

Funder types: Industry

Identifiers

NCT03184480

207580

Details and patient eligibility

About

The aim of this post-marketing investigation is to collect and assess the information about safety and effectiveness of ARNUITY® ELLIPTA® (hereinafter referred to as "Arnuity") in daily clinical practice. The investigation will include subjects with a diagnosis of asthma bronchial who are naïve to ARNUITY. The investigator will monitor the information about safety and effectiveness of ARNUITY for one year from the start date of ARNUITY administration and Pneumonia will be considered as the priority investigation matter. 300 subjects, from approximately 150 medical institutions, will be included in this analysis. ARNUITY ELLIPTA is the registered trademark of GlaxoSmithKline (GSK) group of companies.

Enrollment: 336 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• The investigation will include subjects with a diagnosis of asthma bronchial, for which Arnuity is indicated and who are naïve to Arnuity.

Exclusion criteria

• Not applicable

Trial design

336 participants in 1 patient group

SUBJECTS RECEIVING ARNUITY ELLIPTA

Description:

Subjects with a diagnosis of asthma bronchial, for which Arnuity is indicated, who are naïve to Arnuity will be included.

Treatment:

Drug: Arnuity Ellipta